Back to Search
Start Over
Combination treatments with immunotherapy in brain metastases patients.
- Source :
-
Future oncology (London, England) [Future Oncol] 2020 Aug; Vol. 16 (23), pp. 1691-1705. Date of Electronic Publication: 2020 May 15. - Publication Year :
- 2020
-
Abstract
- Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many advanced cancers. However, in most pivotal trials, patients with brain metastases (BM) were either excluded, or only selected patients were allowed. Therefore, there are still some concerns about the safety/efficacy ratio of ICI in patients with BM. In this special report we will provide an overview on the biological rationale for using ICI in the treatment of BM, the reported BM-related outcomes of clinical trials with a focus on ICI plus chemotherapy and ICI plus ICI combinations. Last, we will provide future challenges with this strategy, as well as directions for future research.
- Subjects :
- Brain Neoplasms immunology
Brain Neoplasms secondary
Clinical Trials as Topic
Drug Therapy, Combination
Humans
Lung Neoplasms immunology
Lung Neoplasms pathology
Prognosis
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Brain Neoplasms drug therapy
Immune Checkpoint Inhibitors therapeutic use
Lung Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8301
- Volume :
- 16
- Issue :
- 23
- Database :
- MEDLINE
- Journal :
- Future oncology (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 32412817
- Full Text :
- https://doi.org/10.2217/fon-2020-0156